Quelles complications peuvent survenir avec des anomalies des MAR ?
Les complications incluent des troubles du développement et un risque accru de cancers.
ComplicationsTroubles du développement
#2
Les anomalies des MAR peuvent-elles entraîner des maladies chroniques ?
Oui, certaines anomalies peuvent contribuer à des maladies chroniques comme le cancer.
Maladies chroniquesCancers
#3
Y a-t-il des complications liées aux traitements des MAR ?
Les traitements peuvent avoir des effets secondaires, mais pas spécifiquement liés aux MAR.
Effets secondairesTraitements
#4
Les complications sont-elles réversibles ?
Certaines complications peuvent être gérées, mais d'autres peuvent être permanentes.
RéversibilitéGestion des complications
#5
Les anomalies des MAR affectent-elles la fertilité ?
Certaines anomalies peuvent influencer la fertilité, mais cela dépend du contexte génétique.
FertilitéAnomalies génétiques
Facteurs de risque
5
#1
Quels sont les facteurs de risque pour les anomalies des MAR ?
Les facteurs incluent des prédispositions génétiques et des expositions environnementales.
Facteurs de risquePrédispositions génétiques
#2
L'âge influence-t-il les anomalies des MAR ?
Oui, l'âge avancé peut augmenter le risque de mutations génétiques, y compris dans les MAR.
ÂgeMutations génétiques
#3
Le mode de vie affecte-t-il les MAR ?
Oui, des habitudes comme le tabagisme et l'alimentation peuvent influencer les MAR.
Mode de vieTabagisme
#4
Les antécédents familiaux jouent-ils un rôle ?
Oui, des antécédents familiaux de maladies génétiques peuvent augmenter le risque d'anomalies.
Antécédents familiauxMaladies génétiques
#5
Les agents environnementaux influencent-ils les MAR ?
Oui, l'exposition à des agents cancérigènes peut affecter l'intégrité des MAR.
Agents environnementauxCancers
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Régions d'ancrage à la matrice nucléaire : Questions médicales les plus fréquentes",
"headline": "Régions d'ancrage à la matrice nucléaire : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Régions d'ancrage à la matrice nucléaire : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-10",
"dateModified": "2025-04-06",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Régions d'ancrage à la matrice nucléaire"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Structures génétiques",
"url": "https://questionsmedicales.fr/mesh/D040342",
"about": {
"@type": "MedicalCondition",
"name": "Structures génétiques",
"code": {
"@type": "MedicalCode",
"code": "D040342",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "G05.360"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Régions d'ancrage à la matrice nucléaire",
"alternateName": "Matrix Attachment Regions",
"code": {
"@type": "MedicalCode",
"code": "D045170",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Tian-Yun Wang",
"url": "https://questionsmedicales.fr/author/Tian-Yun%20Wang",
"affiliation": {
"@type": "Organization",
"name": "Department of Biochemistry and Molecular Biology, Xinxiang Medical University, Xinxiang 453003, Henan, China."
}
},
{
"@type": "Person",
"name": "Xiao-Yin Wang",
"url": "https://questionsmedicales.fr/author/Xiao-Yin%20Wang",
"affiliation": {
"@type": "Organization",
"name": "Department of Biochemistry and Molecular Biology, Xinxiang Medical University, Xinxiang 453003, Henan, China."
}
},
{
"@type": "Person",
"name": "Yan-Long Jia",
"url": "https://questionsmedicales.fr/author/Yan-Long%20Jia",
"affiliation": {
"@type": "Organization",
"name": "Pharmacy Collage, Xinxiang Medical University, Xinxiang 453003, Henan, China."
}
},
{
"@type": "Person",
"name": "Xiao Guo",
"url": "https://questionsmedicales.fr/author/Xiao%20Guo",
"affiliation": {
"@type": "Organization",
"name": "Department of Biochemistry and Molecular Biology, Xinxiang Medical University, Xinxiang 453003, Henan, China; International Joint Research Laboratory for Recombinant Pharmaceutical Protein Expression System of Henan, Xinxiang Medical University, Xinxiang 453003, Henan, China."
}
},
{
"@type": "Person",
"name": "Lubna Anis",
"url": "https://questionsmedicales.fr/author/Lubna%20Anis",
"affiliation": {
"@type": "Organization",
"name": "Owerko Centre for Children's Neurodevelopment and Mental Health, Alberta Children's Hospital Research Institute, Faculty of Nursing, University of Calgary, Calgary, AB T2N 1N4, Canada."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Sensory and motor correlates of frailty: dissociation between frailty phenotype and frailty index.",
"datePublished": "2022-09-15",
"url": "https://questionsmedicales.fr/article/36109693",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12877-022-03416-6"
}
},
{
"@type": "ScholarlyArticle",
"name": "The Japan Frailty Scale is a promising screening test for frailty and pre-frailty in Japanese elderly people.",
"datePublished": "2022-08-22",
"url": "https://questionsmedicales.fr/article/36007804",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.gene.2022.146775"
}
},
{
"@type": "ScholarlyArticle",
"name": "Vascular frailty, a proposal for new frailty type: A narrative review.",
"datePublished": "2023-03-03",
"url": "https://questionsmedicales.fr/article/36866657",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/kjm2.12664"
}
},
{
"@type": "ScholarlyArticle",
"name": "Frailty repels the knife: The impact of frailty index on surgical intervention and outcomes.",
"datePublished": "2022-05-20",
"url": "https://questionsmedicales.fr/article/35599168",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ygyno.2022.05.009"
}
},
{
"@type": "ScholarlyArticle",
"name": "Midlife Life's Simple 7, Psychosocial Health, and Physical Frailty, Hospital Frailty, and Comprehensive Frailty 10 Years Later.",
"datePublished": "2023-05-22",
"url": "https://questionsmedicales.fr/article/37242295",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/nu15102412"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Phénomènes génétiques",
"item": "https://questionsmedicales.fr/mesh/D055614"
},
{
"@type": "ListItem",
"position": 3,
"name": "Structures génétiques",
"item": "https://questionsmedicales.fr/mesh/D040342"
},
{
"@type": "ListItem",
"position": 4,
"name": "Régions d'ancrage à la matrice nucléaire",
"item": "https://questionsmedicales.fr/mesh/D045170"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Régions d'ancrage à la matrice nucléaire - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Régions d'ancrage à la matrice nucléaire",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-04",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Régions d'ancrage à la matrice nucléaire",
"description": "Comment identifier les MAR dans le génome ?\nQuels tests sont utilisés pour étudier les MAR ?\nLes MAR sont-elles visibles par microscopie ?\nPeut-on détecter des mutations dans les MAR ?\nLes MAR sont-elles associées à des maladies ?",
"url": "https://questionsmedicales.fr/mesh/D045170?mesh_terms=Frailty#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Régions d'ancrage à la matrice nucléaire",
"description": "Quels symptômes sont liés aux anomalies des MAR ?\nLes MAR affectent-elles l'expression génique ?\nY a-t-il des symptômes associés aux cancers liés aux MAR ?\nLes MAR influencent-elles le développement embryonnaire ?\nLes anomalies des MAR peuvent-elles causer des troubles ?",
"url": "https://questionsmedicales.fr/mesh/D045170?mesh_terms=Frailty#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Régions d'ancrage à la matrice nucléaire",
"description": "Peut-on prévenir les anomalies des MAR ?\nY a-t-il des tests de dépistage pour les anomalies des MAR ?\nComment réduire le risque de cancers liés aux MAR ?\nL'alimentation influence-t-elle les MAR ?\nLes examens médicaux réguliers aident-ils ?",
"url": "https://questionsmedicales.fr/mesh/D045170?mesh_terms=Frailty#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Régions d'ancrage à la matrice nucléaire",
"description": "Y a-t-il des traitements ciblant les MAR ?\nComment les thérapies géniques affectent-elles les MAR ?\nLes traitements du cancer affectent-ils les MAR ?\nPeut-on utiliser des médicaments pour moduler les MAR ?\nLes interventions chirurgicales peuvent-elles affecter les MAR ?",
"url": "https://questionsmedicales.fr/mesh/D045170?mesh_terms=Frailty#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Régions d'ancrage à la matrice nucléaire",
"description": "Quelles complications peuvent survenir avec des anomalies des MAR ?\nLes anomalies des MAR peuvent-elles entraîner des maladies chroniques ?\nY a-t-il des complications liées aux traitements des MAR ?\nLes complications sont-elles réversibles ?\nLes anomalies des MAR affectent-elles la fertilité ?",
"url": "https://questionsmedicales.fr/mesh/D045170?mesh_terms=Frailty#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Régions d'ancrage à la matrice nucléaire",
"description": "Quels sont les facteurs de risque pour les anomalies des MAR ?\nL'âge influence-t-il les anomalies des MAR ?\nLe mode de vie affecte-t-il les MAR ?\nLes antécédents familiaux jouent-ils un rôle ?\nLes agents environnementaux influencent-ils les MAR ?",
"url": "https://questionsmedicales.fr/mesh/D045170?mesh_terms=Frailty#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment identifier les MAR dans le génome ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les MAR peuvent être identifiées par des techniques de séquençage et d'analyse bioinformatique."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour étudier les MAR ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests comme la PCR et l'hybridation in situ sont couramment utilisés."
}
},
{
"@type": "Question",
"name": "Les MAR sont-elles visibles par microscopie ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, les MAR ne sont pas directement visibles, mais leur effet sur la structure peut l'être."
}
},
{
"@type": "Question",
"name": "Peut-on détecter des mutations dans les MAR ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des mutations dans les MAR peuvent être détectées par séquençage ciblé."
}
},
{
"@type": "Question",
"name": "Les MAR sont-elles associées à des maladies ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines MAR peuvent être liées à des maladies génétiques ou à des cancers."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés aux anomalies des MAR ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les anomalies des MAR peuvent entraîner des dysfonctionnements cellulaires, mais pas de symptômes spécifiques."
}
},
{
"@type": "Question",
"name": "Les MAR affectent-elles l'expression génique ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les MAR jouent un rôle crucial dans la régulation de l'expression génique."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes associés aux cancers liés aux MAR ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes dépendent du type de cancer, mais peuvent inclure fatigue, douleur, et perte de poids."
}
},
{
"@type": "Question",
"name": "Les MAR influencent-elles le développement embryonnaire ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les MAR sont impliquées dans la régulation des gènes essentiels au développement embryonnaire."
}
},
{
"@type": "Question",
"name": "Les anomalies des MAR peuvent-elles causer des troubles ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des anomalies peuvent contribuer à des troubles du développement ou des cancers."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les anomalies des MAR ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention est difficile, mais un mode de vie sain peut réduire les risques de maladies associées."
}
},
{
"@type": "Question",
"name": "Y a-t-il des tests de dépistage pour les anomalies des MAR ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de tests de dépistage spécifiques pour les anomalies des MAR."
}
},
{
"@type": "Question",
"name": "Comment réduire le risque de cancers liés aux MAR ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter les facteurs de risque connus comme le tabagisme et l'exposition à des agents cancérigènes."
}
},
{
"@type": "Question",
"name": "L'alimentation influence-t-elle les MAR ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée peut influencer l'expression génique, y compris celle des MAR."
}
},
{
"@type": "Question",
"name": "Les examens médicaux réguliers aident-ils ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des examens réguliers peuvent aider à détecter précocement des maladies associées."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements ciblant les MAR ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de traitements spécifiques ciblant les MAR."
}
},
{
"@type": "Question",
"name": "Comment les thérapies géniques affectent-elles les MAR ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les thérapies géniques peuvent modifier l'expression des gènes associés aux MAR."
}
},
{
"@type": "Question",
"name": "Les traitements du cancer affectent-ils les MAR ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains traitements du cancer peuvent influencer l'activité des MAR."
}
},
{
"@type": "Question",
"name": "Peut-on utiliser des médicaments pour moduler les MAR ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des recherches sont en cours pour développer des médicaments modulant l'activité des MAR."
}
},
{
"@type": "Question",
"name": "Les interventions chirurgicales peuvent-elles affecter les MAR ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Indirectement, en modifiant l'environnement cellulaire, mais pas directement les MAR."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec des anomalies des MAR ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des troubles du développement et un risque accru de cancers."
}
},
{
"@type": "Question",
"name": "Les anomalies des MAR peuvent-elles entraîner des maladies chroniques ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines anomalies peuvent contribuer à des maladies chroniques comme le cancer."
}
},
{
"@type": "Question",
"name": "Y a-t-il des complications liées aux traitements des MAR ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements peuvent avoir des effets secondaires, mais pas spécifiquement liés aux MAR."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais d'autres peuvent être permanentes."
}
},
{
"@type": "Question",
"name": "Les anomalies des MAR affectent-elles la fertilité ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines anomalies peuvent influencer la fertilité, mais cela dépend du contexte génétique."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour les anomalies des MAR ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des prédispositions génétiques et des expositions environnementales."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il les anomalies des MAR ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'âge avancé peut augmenter le risque de mutations génétiques, y compris dans les MAR."
}
},
{
"@type": "Question",
"name": "Le mode de vie affecte-t-il les MAR ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des habitudes comme le tabagisme et l'alimentation peuvent influencer les MAR."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux jouent-ils un rôle ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de maladies génétiques peuvent augmenter le risque d'anomalies."
}
},
{
"@type": "Question",
"name": "Les agents environnementaux influencent-ils les MAR ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à des agents cancérigènes peut affecter l'intégrité des MAR."
}
}
]
}
]
}
Department of Biochemistry and Molecular Biology, Xinxiang Medical University, Xinxiang 453003, Henan, China.
International Joint Research Laboratory for Recombiant Pharmaceutical Protein Expression System of Henan, Xinxiang Medical University, Xinxiang 453003, Henan, China.
Publications dans "Régions d'ancrage à la matrice nucléaire" :
Department of Biochemistry and Molecular Biology, Xinxiang Medical University, Xinxiang 453003, Henan, China.
International Joint Research Laboratory for Recombiant Pharmaceutical Protein Expression System of Henan, Xinxiang Medical University, Xinxiang 453003, Henan, China.
Publications dans "Régions d'ancrage à la matrice nucléaire" :
Department of Biochemistry and Molecular Biology, Xinxiang Medical University, Xinxiang 453003, Henan, China; International Joint Research Laboratory for Recombinant Pharmaceutical Protein Expression System of Henan, Xinxiang Medical University, Xinxiang 453003, Henan, China.
Publications dans "Régions d'ancrage à la matrice nucléaire" :
Owerko Centre for Children's Neurodevelopment and Mental Health, Alberta Children's Hospital Research Institute, Faculty of Nursing, University of Calgary, Calgary, AB T2N 1N4, Canada.
Publications dans "Régions d'ancrage à la matrice nucléaire" :
Owerko Centre for Children's Neurodevelopment and Mental Health, Alberta Children's Hospital Research Institute, University of Calgary, Calgary, AB T2N 1N4, Canada.
Publications dans "Régions d'ancrage à la matrice nucléaire" :
Owerko Centre for Children's Neurodevelopment and Mental Health, Alberta Children's Hospital Research Institute, Departments of Pediatrics, Psychiatry, and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 1N4, Canada.
Publications dans "Régions d'ancrage à la matrice nucléaire" :
International Joint Research Laboratory for Recombiant Pharmaceutical Protein Expression System of Henan, Xinxiang Medical University, Xinxiang 453003, Henan, China.
Publications dans "Régions d'ancrage à la matrice nucléaire" :
Department of Biochemistry and Molecular Biology, Xinxiang Medical University, Xinxiang 453003, Henan, China.
International Joint Research Laboratory for Recombiant Pharmaceutical Protein Expression System of Henan, Xinxiang Medical University, Xinxiang 453003, Henan, China.
Publications dans "Régions d'ancrage à la matrice nucléaire" :
Department of Biochemistry and Molecular Biology, Xinxiang Medical University, Xinxiang 453003, Henan, China; International Joint Research Laboratory for Recombinant Pharmaceutical Protein Expression System of Henan, Xinxiang Medical University, Xinxiang 453003, Henan, China.
Publications dans "Régions d'ancrage à la matrice nucléaire" :
State Key Laboratory of Environmental Chemistry and Ecotoxicology, Research Center for Eco-Environmental Sciences, Chinese Academy of Sciences, Beijing 100085, China.
University of Chinese Academy of Sciences, Beijing 100049, China.
Publications dans "Régions d'ancrage à la matrice nucléaire" :
Frailty has been associated with a decline in sensory and motor function. However, given that different frailty measures were shown to overlap but also differ in their diagnostic properties, sensory a...
Data from 44 pre-frail and frail subjects aged 65 and above were used. Frailty was measured using the FP and the FI. Sensory function in the visual, auditory, and tactile domain was assessed using vis...
The frailty measures were moderately correlated (0.497, p ≤ 0.01) and had a Kappa agreement of 0.467 (p = 0.002). Using the FP, frailty was significantly associated with reduced upper extremity motor ...
Frailty is related to reduced performance in measures of sensory and motor function. However, traditional measures of frailty might be differentially sensitive to capture sensory and motor decline, po...
ClinicalTrials.gov NCT03666039 . Registered 11 September 2018 - Retrospectively registered....
Frailty is one of the most important problems in a super-aged society. It is necessary to identify frailty quickly and easily at the bedside. We developed a simple patient-reported frailty screening s...
Frailty is the incremental accumulation of minute defects that progressively impair health and performance. Frailty is commonly observed in older adults; however, secondary frailty may also occur in p...
To assess the impact of frailty in patients with ovarian cancer on surgical procedures and outcomes....
A retrospective review of patients with stage II-IV ovarian cancer from April 2013 to September 2017 was performed. Patients were triaged by laparoscopy to determine primary resectability. The adjuste...
592 patients met inclusion criteria; amFI of 0, 1 and ≥ 2 was noted in 57%, 29%, and 14%, respectively. Patients with high frailty were less likely to be offered laparoscopic assessment for primary su...
Postoperative morbidity, PFS, and OS were worse in patients with high frailty scores. Quantification of frailty may be useful for clinical decision making in patients with newly diagnosed advanced ova...
This study aims to examine the associations between midlife Life's Simple 7 (LS7) status, psychosocial health (social isolation and loneliness), and late-life multidimensional frailty indicators, and ...
The Clinical Frailty Scale (CFS) is a simple and validated tool for assessing frailty, and higher CFS scores are correlated with worse perioperative outcomes after cardiovascular surgery. However, the...
We retrospectively analyzed data from 561 patients with esophageal cancer (EC) who underwent resection from August 2010 to August 2020. We defined a CFS score of ≥4 as indicative of frailty; thus, pat...
Of the 561 patients, 90 (16%) had frailty and 471 (84%) did not. Frail patients had a significantly older age, lower body mass index, higher American Society of Anesthesiologists physical status class...
Preoperative frailty was associated with shorter OS after resection of EC. The CFS score may be a prognostic biomarker for patients with EC, especially early-stage EC....
With the topical focus on the prevention of and countermeasures for frailty, scattered studies have subdivided its social elements and aspects as "social frailty." While the concepts and definition of...
Frailty is a common condition present in older Emergency Department (ED) patients that is associated with poor health outcomes. The Clinical Frailty Scale (CFS) is a tool that measures frailty on a sc...
We performed a systemic literature search to identify original research that used the CFS in emergency medicine. Several databases were searched from January 2005 to July 2021. Two independent reviewe...
A total of 4818 unique citations were identified; 34 studies were included in the final analysis. Among them, 76% were published after 2018, mainly in Europe or North America (79%). Only two assessed ...
The use of CFS in emergency medicine research is drastically increasing. However, the reporting is not optimal and should be more standardized. Studies evaluating the impact of frailty assessment in t...
https://doi.org/10.17605/OSF.IO/W2F8N....
To test the agreement of the Clinical Frailty Scale (CFS) and the Tilburg Frailty Indicator (TFI), their association with 3, 6 months and 1-year mortality and the trajectory of frailty in a mixed popu...
This is a prospective, multicenter, longitudinal study on ICU survivors ≥18 years old with an ICU stay >72 h. For each patient, sociodemographic and clinical data were collected. Frailty was assessed ...
124 patients with a mean age of 66 years old were enrolled. The baseline prevalence of frailty was 15.3% by CFS and 44.4% by TFI. Baseline CFS and TFI correlated but showed low agreement (Cohen's K = ...
CFS and TFI identify different populations of frail ICU survivors. Frail patients before ICU according to CFS have a significantly higher mortality after ICU discharge. The CFS during follow-up is an ...
Muscles and bones are intricately connected tissues displaying marked co-variation during development, growth, aging, and in many diseases. While the diagnosis and treatment of osteoporosis are well e...